Psilocybin: Counterculture to Cutting-Edge Psychiatry

Are psychedelics poised to transform mental health treatment? Connor Williams joins Stephanie Sirota for a deep dive into psilocybin, the science behind its effects on the brain, and its potential in treatment-resistant depression, PTSD, and other serious conditions. As clinical trials advance and FDA pathways take shape, psychedelics have moved from counterculture to clinic, raising critical questions for patients, clinicians, and investors alike.PODCAST TEAMProducer & Director: Devon LeaverEditor: Dominique GuerraProduction Coordinator: Ying Yu LinProduction support: Annabelle ChanExecutive Editorial Advisor: Stephanie SirotaResearch Consultant: Connor WilliamsTheme music: Yehezkel RazAdditional music: APM MusicFeaturing: Senior Research Analyst, Connor Williams, and moderated by Stephanie Sirota, Partner and Chief Business Officer at RTW InvestmentsStay tuned for part 2 of Stephanie's discussion on Psychedelics with Dr. Steve Levine, Chief Patient Officer at Compass Pathways.FOLLOW USLove our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.CHAPTERS00:00 - Introduction1:12 - Explaining Psilocybin 4:21 – Recreational Use to Medical Use 6:03 - Compass Pathways’ Story 11:18 - Getting Psychedelics to Patients 16:04 - Myth or Fact: Psilocybin 21:15 - What’s next for Psilocybin? 20:02 - OutroDISCLAIMERThis interview was given by Senior Research Analyst, Connor Williams, and moderated by Stephanie Sirota, Partner and Chief Business Officer at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.